With biologics dominating its pipeline, Sanofi will spend as much as $2 billion on its biologics manufacturing network over the next several years.

Argentina's Sinergium Biotech, which is in a consortium to develop a Zika virus vaccine, intends to build a new plant that will use cell biology that can…

All of Wockhardt's U.S. targeted  manufacturing facilities are under some kind of FDA oversight, but the Indian generics maker got a new product approved…

The FDA and the European Medicines Agency have agreed to recognize the plant inspections each does in their own areas.

Sanofi and Swiss contractor Lonza will share the cost of building a €270 million ($286.3 million) plant to expand capacity for new biologic meds.

South San Francisco-based Portola Pharmaceuticals has snagged $50 million in loans from Pfizer and Bristol-Myers Squibb to help cover the additional costs tied…

A North Carolina company that makes transdermal patches has gotten an FDA warning letter for releasing subpotent transdermal pain patches.

Contract manufacturer Fareva has completed an aerosol plant in Virginia but is considering a second upgrade that would more than double capacity at the…